Extended Data Fig. 1: Anti-progestin treatment suppresses serum progesterone and reduces LP cell activity and frequency.
From: Anti-progestin therapy targets hallmarks of breast cancer risk
A) Measurement of serum progesterone levels before (baseline) and after (post-treatment) 3 months of ulipristal acetate (N = 24 pairs). B) Average area of acinar structures within lobules before (baseline) and after (post-treatment) 3 months of UA therapy (N = 17 tissue pairs). C) Number of acinar structures per area (µm2) of lobules before (baseline) and after (post-treatment) 3 months of UA therapy (N = 19 tissue pairs). D) Gating strategy used to assess breast epithelial cell populations via flow cytometry. Live cell-sized singlets were selected from samples lineage depleted and stained with EpCAM and CD49f antibodies. E) Representative examples of luminal, mixed and basal colonies formed in the clonogenic assay are shown. Scale bar = 50 μm. N = 18 tissue pairs. F) Mammosphere formation efficiency (MFE %) data for baseline cell suspensions in the presence of onapristone (100 nM) versus control (DMSO). N = 14 baseline tissue. G) Mammosphere formation efficiency (MFE %) data for baseline cell suspensions in the presence of ulipristal acetate (2 nM) versus control (ethanol). N = 6 baseline tissue. H) Percentage of SOX9+ cells in pairs of tissue quantified by immunofluorescence. N = 10 tissue pairs. Box plots centre lines represent median values and box bounds indicate the 25th and 75th percentiles, with connecting lines between paired data points; p values are calculated with two-sided Wilcoxon matched-pairs signed rank test (A-C, F-H).
